Ask about this productRelated genes to: CD80 antibody
- Gene:
- CD80 NIH gene
- Name:
- CD80 molecule
- Previous symbol:
- CD28LG, CD28LG1
- Synonyms:
- B7.1, B7-1
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-14
- Date modifiied:
- 2016-10-05
Related products to: CD80 antibody
Related articles to: CD80 antibody
- Adjuvants, which enhance the effectiveness of antigens, are essential for vaccines against infectious or malignant diseases. Currently, the development of adjuvants encounters challenges as highly effective adjuvants tend to be highly toxic, whereas those with lower toxicity often lack efficacy. Polysaccharides have unique advantages as adjuvants due to their multiple immunomodulatory activities and favorable safety profiles. In this study, longan polysaccharide (LP) was characterized physicochemically and identified as an effective adjuvant. LP, consisting of 96.44% glucose, was mainly linked by the α-1,6-glycosidic bond. In vitro experiments revealed that LP could induce the secretion of pro-inflammatory cytokines (TNF-α, IL12, and IL1β) and expression of co-stimulatory molecules (CD80 and CD86) through toll-like receptor 4 (TLR4) activation. More importantly, LP could promote antigen cross-presentation when formulated with a model antigen-ovalbumin (OVA). In vivo experiments indicated that the LP+OVA formulation could boost both humoral and cellular immune responses in immunized C57BL/6J mice. The histopathological evaluation of the major organs showed that LP+OVA was non-toxic. Therefore, our findings suggested that LP is an effective and safe adjuvant for vaccine development. - Source: PubMed
Publication date: 2026/04/29
Xie Da-PingZhuang Zi-HaoJin Ming-YuYu Ya-HuiYan Jing-Kun - Anti-synthetase syndrome (ASS) is an autoimmune disease characterized by serum anti-aminoacyl-tRNA synthetase (ARS) antibodies and frequently associated with recurrent and refractory interstitial lung disease (ASS-ILD). Its pathogenesis remains poorly understood. - Source: PubMed
Publication date: 2026/05/12
Su KaishengQi TuanHe JiangpingZhang XiaofangLiu LeiZhou YanziGu JueqingYi CaihongWang JundiWang LiminWang JiaoliXia JunboJin XuediChang XingZhang ChuZhang FengchunHuang Jiao - Porcine epidemic diarrhea (PED) is a highly lethal and airborne disease in neonatal piglets that has caused significant economic losses in the pig industry over the last three decades. Despite the widespread implementation of commercial vaccines, the disease continues to exhibit recurrent outbreaks, primarily owing to suboptimal immunization efficacy. In this study, we engineered recombinant LP12:PEDV tS1, which expresses the truncated S1 domain of the porcine epidemic diarrhea virus (PEDV) spike protein through a surface anchoring mechanism. The expression was confirmed using western blotting, flow cytometry, and indirect immunofluorescence assays, with a maximum protein yield of 1.7657 μg per 1 × 10 CFU. Furthermore, we immunized mice and pigs nasally with LP12:PEDV tS1 separately. Immunization elicited robust mucosal immune responses, as evidenced by a significant increase in specific secretory IgA (sIgA) with neutralizing activity in alveolar lavage fluid and fecal samples. Our results also indicated that LP12:PEDV tS1 activated dendritic cells in the mesenteric lymph nodes of mice, marked by notable upregulation of CD80 and CD86. Successive immunization with LP12:PEDV tS1 protected piglets from PEDV infection and elicited comparable mucosal immune responses across species, demonstrating its strong potential as a PEDV vaccine candidate. Moreover, an intranasal immunization strategy based on recombinant demonstrated suitability for cross-species vaccination between mice and piglets, potentially streamlining the preclinical evaluation process.IMPORTANCEPorcine epidemic diarrhea (PED) is a major cause of piglet mortality. Current control relies on vaccinating pregnant sows with inactivated or attenuated viruses. However, not all sows develop sufficient antibodies to protect piglets. Once piglets are infected, no effective emergency vaccines are available for them, as existing options pose biosafety risks. To address this, we developed a subunit mucosal vaccine using recombinant . This vaccine is cost-effective, enables cross-species immunization, and remarkably provides immediate immunity to prevent viral infection in neonatal piglets. - Source: PubMed
Publication date: 2026/05/11
Hao JiayiZhou XieshenZhang GuoqingDeng LingcongLi LetianWang Maopeng - Macrophage polarization into M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes is essential for immune responses and tissue homeostasis. While transcriptional and post-transcriptional mechanisms controlling this process have been characterized, the contribution of alternative mRNA polyadenylation (APA) to polarization requires clarification. Using human monocytic cell lines, we demonstrate that CFIm25, a key APA regulator, controls macrophage polarization states. CFIm25 overexpression enhances M1 characteristics, including nitric oxide production, CD80 expression, pro-inflammatory cytokine secretion, phagocytosis, migration, and cancer cell killing, while suppressing M2 traits. CFIm25 knockdown produces opposite effects. Mechanistically, CFIm25 promotes the proximal polyadenylation of AKT2 mRNA, generating shorter transcripts with enhanced stability and translational efficiency that increase Akt2 protein levels and amplify NF-κB signaling. Blocking the proximal site with antisense oligonucleotides reduces Akt2 expression and induces M2-like phenotypes. These findings establish APA as a critical regulator of macrophage polarization and identify the CFIm25-Akt2-NF-κB axis as a potential therapeutic target for modulating immune responses. - Source: PubMed
Publication date: 2026/04/20
Mukherjee SrimoyeeBarua AtishNaseri MarziehMoore Claire L - Renal carcinoma remains a highly lethal malignancy, and tumor vaccine efficacy is frequently hampered by a profoundly immunosuppressive tumor microenvironment. V-domain Ig suppressor of T-cell activation (VISTA), an inhibitory immune checkpoint enriched in myeloid cells and regulatory T cells (Tregs), represents a critical barrier to effective antitumor immunity. Targeting VISTA may therefore provide a promising strategy to overcome immune suppression and enhance tumor vaccine efficacy. - Source: PubMed
Publication date: 2026/05/08
Wang JiaweiWang ZhenzhenZhao WantingChen HaominLu BowenShao YingxiangZheng YanyanLiu ShanshanWang MengFang LinLi HuizhongNeeli PraveenTian HuiWang GangChai Dafei